Sana Biotechnology, Inc. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
Sana Biotechnology, Inc. (SANA) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $2.06 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2026-08-10
- Sana Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-12-31 was $0.00.
- Sana Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-09-30 was $0.00.
- Sana Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- Sana Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for the quarter ending 2023-03-31 was $8.98M, a 161.85% increase year-over-year.
- Sana Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2025 was $0.00.
- Sana Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Sana Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $8.98M, a 57.37% decline from fiscal 2022.
- Sana Biotechnology, Inc. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $21.07M, a 47.31% decline from fiscal 2021.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 3 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 6 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 9 month | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.06M 10-Q · filed 2026-08-10 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-03-03 | |||
| 2025-06-30 | $0.00 10-Q · filed 2026-08-10 | |||
| 2024-12-31 | $0.00 10-K · filed 2026-03-03 | |||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $0.00 derived: sum of 2 quarters · filed 2026-03-03 | $0.00 derived: sum of 3 quarters · filed 2026-03-03 | $8.98M 10-K · filed 2026-03-03 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $0.00 derived: sum of 2 quarters · filed 2024-11-08 | $8.98M 10-Q · filed 2024-11-08 | $8.98M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $8.98M 10-Q · filed 2024-08-08 | $8.98M derived: sum of 3 quarters · filed 2025-03-17 | $8.98M derived: sum of 4 quarters · filed 2025-03-17 |
| 2023-03-31 | $8.98M 10-Q · filed 2024-05-08 | $8.98M derived: sum of 2 quarters · filed 2025-03-17 | $8.98M derived: sum of 3 quarters · filed 2025-03-17 | $26.63M derived: sum of 4 quarters · filed 2025-03-17 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $0.00 derived: sum of 2 quarters · filed 2025-03-17 | $17.64M derived: sum of 3 quarters · filed 2025-03-17 | $21.07M 10-K · filed 2025-03-17 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $17.64M derived: sum of 2 quarters · filed 2023-11-08 | $21.07M 10-Q · filed 2023-11-08 | $34.81M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | $17.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | $21.07M 10-Q · filed 2023-08-03 | $34.81M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2022-03-31 | $3.43M 10-Q · filed 2023-05-08 | $17.17M derived: sum of 2 quarters · filed 2024-02-29 | ||
| 2021-12-31 | $13.74M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $40.00M 10-K · filed 2024-02-29 | ||
| 2021-09-30 | $26.26M 10-Q · filed 2022-11-02 | |||
| 2020-12-31 | $3.47M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $6.55M derived: sum of 2 quarters · filed 2023-03-16 | $12.25M derived: sum of 3 quarters · filed 2023-03-16 | $26.52M 10-K · filed 2023-03-16 |
| 2020-09-30 | $3.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | $8.78M derived: sum of 2 quarters · filed 2021-11-08 | $23.05M 10-Q · filed 2021-11-08 | |
| 2020-06-30 | $5.70M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | $19.97M 10-Q · filed 2021-08-04 | ||
| 2020-03-31 | $14.27M 10-Q · filed 2021-05-05 | |||
| 2019-12-31 | $48.86M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |